PRECIGEN, INC. Revenues
PRECIGEN, INC. (PGEN) reported Revenues of $17.00 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2020-03-02
- PRECIGEN, INC. revenues for the quarter ending 2019-12-31 was $17.00M, a 58.72% decline year-over-year.
- PRECIGEN, INC. revenues for the quarter ending 2019-09-30 was $18.30M, a 39.11% decline year-over-year.
- PRECIGEN, INC. revenues for the quarter ending 2019-06-30 was $32.84M, a 23.23% decline year-over-year.
- PRECIGEN, INC. revenues for the quarter ending 2019-03-31 was $22.59M, a 39.22% decline year-over-year.
- PRECIGEN, INC. revenues for fiscal 2017 was $230.98M, a 20.98% increase from fiscal 2016.
- PRECIGEN, INC. revenues for fiscal 2016 was $190.93M, a 9.98% increase from fiscal 2015.
- PRECIGEN, INC. revenues for fiscal 2015 was $173.60M, a 141.35% increase from fiscal 2014.
- PRECIGEN, INC. revenues for fiscal 2014 was $71.93M, a 202.74% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | $17.00M 10-K · filed 2020-03-02 | $35.30M derived: sum of 2 quarters · filed 2020-03-02 | $68.14M derived: sum of 3 quarters · filed 2020-03-02 | $90.72M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2019-09-30 | $18.30M 10-K · filed 2020-03-02 | $51.13M derived: sum of 2 quarters · filed 2020-03-02 | $73.72M derived: sum of 3 quarters · filed 2020-03-02 | $114.91M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2019-06-30 | $32.84M 10-K · filed 2020-03-02 | $55.42M derived: sum of 2 quarters · filed 2020-03-02 | $96.61M derived: sum of 3 quarters · filed 2020-03-02 | $126.67M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2019-03-31 | $22.59M 10-K · filed 2020-03-02 | $63.78M derived: sum of 2 quarters · filed 2020-03-02 | $93.83M derived: sum of 3 quarters · filed 2020-03-02 | $136.60M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-12-31 | $41.19M 10-K · filed 2020-03-02 | $43.19M 10-K · filed 2019-03-01 | $71.25M derived: sum of 2 quarters · filed 2020-03-02 | $114.02M derived: sum of 3 quarters · filed 2020-03-02 | $151.18M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-09-30 | $30.05M 10-K · filed 2020-03-02 | $32.45M 10-K · filed 2019-03-01 | $72.83M derived: sum of 2 quarters · filed 2020-03-02 | $109.99M derived: sum of 3 quarters · filed 2020-03-02 | $187.01M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $42.77M 10-K · filed 2020-03-02 | $45.27M 10-Q · filed 2018-08-13 | $84.94M 10-Q · filed 2018-08-13 | $156.96M derived: sum of 3 quarters · filed 2020-03-02 | $202.97M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $37.16M 10-K · filed 2020-03-02 | $43.84M 10-Q · filed 2018-05-10 | $114.19M derived: sum of 2 quarters · filed 2020-03-02 | $160.20M derived: sum of 3 quarters · filed 2020-03-02 | $214.64M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | $77.03M 10-K · filed 2019-03-01 | $123.04M derived: sum of 2 quarters · filed 2019-03-01 | $177.48M derived: sum of 3 quarters · filed 2019-03-01 | $230.98M 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $46.02M 10-K · filed 2019-03-01 | $100.45M derived: sum of 2 quarters · filed 2019-03-01 | $153.95M 10-Q · filed 2017-11-09 | $199.96M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-06-30 | $54.43M 10-K · filed 2019-03-01 | $107.94M 10-Q · filed 2018-08-13 | $153.94M derived: sum of 3 quarters · filed 2019-03-01 | $202.92M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | $53.50M 10-K · filed 2019-03-01 | $53.75M 10-Q · filed 2017-05-10 | $99.51M derived: sum of 2 quarters · filed 2019-03-01 | $148.49M derived: sum of 3 quarters · filed 2019-03-01 | $200.99M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2016-12-31 | $46.00M 10-K · filed 2018-03-01 | $94.99M derived: sum of 2 quarters · filed 2018-03-01 | $147.49M derived: sum of 3 quarters · filed 2018-03-01 | $190.93M 10-K · filed 2018-03-01 | |||
| 2016-09-30 | $48.98M 10-K · filed 2018-03-01 | $101.49M derived: sum of 2 quarters · filed 2018-03-01 | $144.92M 10-Q · filed 2017-11-09 | $186.42M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | $52.50M 10-K · filed 2018-03-01 | $95.94M 10-Q · filed 2017-08-09 | $137.44M derived: sum of 3 quarters · filed 2018-03-01 | $190.80M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | $43.44M 10-K · filed 2018-03-01 | $84.94M derived: sum of 2 quarters · filed 2018-03-01 | $138.30M derived: sum of 3 quarters · filed 2018-03-01 | $183.19M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $41.50M 10-K · filed 2017-03-01 | $94.86M derived: sum of 2 quarters · filed 2017-03-01 | $139.76M derived: sum of 3 quarters · filed 2017-03-01 | $173.60M 10-K · filed 2018-03-01 | |||
| 2015-09-30 | $53.37M 10-K · filed 2017-03-01 | $98.26M derived: sum of 2 quarters · filed 2017-03-01 | $132.11M 10-Q · filed 2016-11-09 | $163.20M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $44.89M 10-K · filed 2017-03-01 | $78.74M 10-Q · filed 2016-08-09 | $109.83M derived: sum of 3 quarters · filed 2017-03-01 | $131.03M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $33.85M 10-K · filed 2017-03-01 | $64.94M derived: sum of 2 quarters · filed 2017-03-01 | $86.14M derived: sum of 3 quarters · filed 2017-03-01 | $97.92M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $31.09M 10-K · filed 2016-02-29 | $52.29M derived: sum of 2 quarters · filed 2016-02-29 | $64.08M derived: sum of 3 quarters · filed 2016-02-29 | $71.93M 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $21.20M 10-K · filed 2016-02-29 | $32.98M derived: sum of 2 quarters · filed 2016-02-29 | $40.84M 10-Q · filed 2015-11-09 | $47.98M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $11.79M 10-K · filed 2016-02-29 | $19.64M 10-Q · filed 2015-08-10 | $26.78M derived: sum of 3 quarters · filed 2016-02-29 | $32.92M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $7.85M 10-K · filed 2016-02-29 | $15.00M derived: sum of 2 quarters · filed 2016-02-29 | $21.13M derived: sum of 3 quarters · filed 2016-02-29 | $27.82M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $7.14M 10-K · filed 2015-03-02 | $13.28M derived: sum of 2 quarters · filed 2015-03-02 | $19.97M derived: sum of 3 quarters · filed 2015-03-02 | $23.76M 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $6.04M 10-K · filed 2015-03-02 | $12.82M derived: sum of 2 quarters · filed 2015-03-02 | $16.62M 10-Q · filed 2014-11-13 | $16.89M 10-Q · filed 2013-11-07 | $23.28M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $6.69M 10-K · filed 2015-03-02 | $6.78M 10-Q/A · filed 2013-10-21 | $10.57M 10-Q · filed 2014-08-14 | $10.76M 10-Q/A · filed 2013-10-21 | $17.14M derived: sum of 3 quarters · filed 2015-03-02 | $20.07M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-03-31 | $3.88M 10-K · filed 2015-03-02 | $10.45M derived: sum of 2 quarters · filed 2015-03-02 | $13.38M derived: sum of 3 quarters · filed 2015-03-02 | $16.09M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $6.57M 10-K · filed 2014-03-31 | $9.49M derived: sum of 2 quarters · filed 2014-03-31 | $12.21M derived: sum of 3 quarters · filed 2014-03-31 | $13.77M 10-K · filed 2015-03-02 | |||
| 2012-09-30 | $2.92M 10-K · filed 2014-03-31 | $5.64M derived: sum of 2 quarters · filed 2014-03-31 | $7.27M 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $2.72M 10-K · filed 2014-03-31 | $2.73M 10-Q/A · filed 2013-10-21 | $4.34M 10-Q/A · filed 2013-10-21 | ||||
| 2012-03-31 | $1.56M 10-K · filed 2014-03-31 | ||||||
| 2011-12-31 | $8.01M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |